Vestal Point Capital LP Cuts Stock Position in Liquidia Co. (NASDAQ:LQDA)

Vestal Point Capital LP trimmed its position in shares of Liquidia Co. (NASDAQ:LQDA) by 18.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,500,000 shares of the company’s stock after selling 330,000 shares during the quarter. Liquidia accounts for approximately 1.1% of Vestal Point Capital LP’s investment portfolio, making the stock its 25th biggest position. Vestal Point Capital LP’s holdings in Liquidia were worth $15,000,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Quest Partners LLC acquired a new position in shares of Liquidia in the second quarter valued at approximately $27,000. Hilltop National Bank acquired a new position in shares of Liquidia in the second quarter worth $33,000. Clear Harbor Asset Management LLC purchased a new stake in shares of Liquidia during the third quarter worth $100,000. Signaturefd LLC raised its stake in shares of Liquidia by 38,400.0% in the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after acquiring an additional 9,984 shares in the last quarter. Finally, Ballentine Partners LLC purchased a new position in Liquidia in the third quarter valued at $110,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 2,576 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the sale, the general counsel now directly owns 486,048 shares of the company’s stock, valued at approximately $5,399,993.28. This trade represents a 0.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajeev Saggar sold 2,260 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $25,108.60. Following the completion of the transaction, the insider now owns 207,383 shares in the company, valued at $2,304,025.13. This trade represents a 1.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,551 shares of company stock worth $236,021. 30.10% of the stock is owned by insiders.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $11.61 on Friday. The business has a 50-day moving average price of $10.70 and a 200 day moving average price of $11.37. Liquidia Co. has a 52-week low of $6.82 and a 52-week high of $16.99.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on LQDA shares. Scotiabank started coverage on Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Lifesci Capital initiated coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. Finally, BTIG Research dropped their target price on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, August 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).